Active surveillance (AS) is an option for low-risk prostate cancer. Accurate risk assessment is paramount to select patients for definitive intervention and to avoid overtreatment. Although inaccurate, PSA and Gleason score changes remain common treatment triggers. Biopsy before AS is initiated could avoid misclassification and the need for serial biopsy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mohler, J. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl Compr. Canc. Netw. 8, 240–262 (2010).
Klotz, L. et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28, 126–131 (2010).
Loblaw, A. et al. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J. Urol. 184, 1942–1946 (2010).
Ross, A. E. et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J. Clin. Oncol. 28, 2810–2816 (2010).
Coen, J. J. et al. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int. doi:10.1111/j.1464-410X.2010.09652.x.
Jeldres, C. et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur. Urol. 54, 1306–1313 (2008).
Epstein, J. I. et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271, 368–374 (1994).
Bastian, P. J. et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur. Urol. 55, 1321–1330 (2009).
Roemeling, S. et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur. Urol. 51, 1244–1250 (2007).
Lin, D. W. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Urol. Oncol. 27, 315–321 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hilton, W., Parekh, D. Treatment triggers for patients on active surveillance. Nat Rev Urol 8, 126–127 (2011). https://doi.org/10.1038/nrurol.2010.235
Published:
Issue date:
DOI: https://doi.org/10.1038/nrurol.2010.235
